These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36706959)

  • 1. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
    Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
    Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
    Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
    NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
    Feng A; Yuan P; Huang T; Li L; Lyu J
    Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
    Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
    El-Abtah ME; Talati P; Fu M; Chun B; Clark P; Peters A; Ranasinghe A; He J; Rapalino O; Batchelor TT; Gilberto Gonzalez R; Curry WT; Dietrich J; Gerstner ER; Ratai EM
    Neurooncol Adv; 2022; 4(1):vdac128. PubMed ID: 36071927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach.
    Di Costanzo A; Scarabino T; Trojsi F; Popolizio T; Bonavita S; de Cristofaro M; Conforti R; Cristofano A; Colonnese C; Salvolini U; Tedeschi G
    Radiol Med; 2014 Aug; 119(8):616-24. PubMed ID: 24408041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
    Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
    J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
    Ratai EM; Zhang Z; Fink J; Muzi M; Hanna L; Greco E; Richards T; Kim D; Andronesi OC; Mintz A; Kostakoglu L; Prah M; Ellingson B; Schmainda K; Sorensen G; Barboriak D; Mankoff D; Gerstner ER;
    PLoS One; 2018; 13(6):e0198548. PubMed ID: 29902200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation analysis of expressions of PTEN and p53 with the value obtained by magnetic resonance spectroscopy and apparent diffusion coefficient in the tumor and the tumor-adjacent area in magnetic resonance imaging for glioblastoma.
    Li Y; Ji F; Jiang Y; Zhao T; Xu C
    J BUON; 2018; 23(2):391-397. PubMed ID: 29745082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
    Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
    Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C
    Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.